148 related articles for article (PubMed ID: 28567600)
21. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
[TBL] [Abstract][Full Text] [Related]
22. Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.
Ali A; Dumbrava M; Riddell K; Stewart N; Ward R; Ibrahim AK; Chin M
BMC Cancer; 2020 Apr; 20(1):342. PubMed ID: 32321474
[TBL] [Abstract][Full Text] [Related]
23. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
24. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib.
Kainthla R; Kim KB; Falchook GS
Recent Results Cancer Res; 2014; 201():227-40. PubMed ID: 24756796
[TBL] [Abstract][Full Text] [Related]
26. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Grob JJ; Amonkar MM; Martin-Algarra S; Demidov LV; Goodman V; Grotzinger K; Haney P; Kämpgen E; Karaszewska B; Mauch C; Miller WH; Millward M; Mirakhur B; Rutkowski P; Chiarion-Sileni V; Swann S; Hauschild A
Ann Oncol; 2014 Jul; 25(7):1428-1436. PubMed ID: 24769640
[TBL] [Abstract][Full Text] [Related]
27. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
Lancet; 2015 Aug; 386(9992):444-51. PubMed ID: 26037941
[TBL] [Abstract][Full Text] [Related]
28. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
32. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
33. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
[TBL] [Abstract][Full Text] [Related]
34. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
36. Late-onset robust curly hair growth in a patient with BRAF-mutated metastatic melanoma responding to dabrafenib.
Keating M; Dasanu CA
J Oncol Pharm Pract; 2017 Jun; 23(4):309-312. PubMed ID: 26946529
[TBL] [Abstract][Full Text] [Related]
37. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
[TBL] [Abstract][Full Text] [Related]
38. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
Rogiers A; Wolter P; Bechter O
Melanoma Res; 2017 Apr; 27(2):164-167. PubMed ID: 28252479
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
